4-(叔丁氧基羰基)苯硼酸 | 850568-54-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(叔丁氧基羰基)苯硼酸
• 中文别名: 4-(叔丁氧羰基)苯硼酸；4-叔丁氧基羰基苯硼酸；4-叔丁氧基羰基苯基硼酸；4-(叔丁氧羰基)苯基硼酸
• 英文名称: (4-(tert-butoxycarbonyl)phenyl)boronic acid
• 英文别名: (p-(tert-butoxycarbonyl)phenyl)boronic acid；(4-t-butoxycarbonylphenyl)boronic acid；[4-[(2-methylpropan-2-yl)oxycarbonyl]phenyl]boronic acid
• CAS: 850568-54-6
• 化学式: C₁₁H₁₅BO₄
• mdl: MFCD03411946
• 分子量: 222.049
• InChiKey: QMVMDYSTJSUDKC-UHFFFAOYSA-N

物化性质

• 熔点：
  100-106°C
• 沸点：
  364.3±44.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.62
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-t-Butoxycarbonylphenylboronic acid
Synonyms: t-Butyl 4-boronobenzoate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-t-Butoxycarbonylphenylboronic acid
CAS number: 850568-54-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H15BO4
Molecular weight: 222.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(4-叔丁氧羰基苯基)硼酸是一种生物化学试剂，可用于生物材料或有机化合物，在生命科学相关研究中发挥重要作用。

反应信息

• 作为反应物：
  描述：

  4-(叔丁氧基羰基)苯硼酸 在 N-溴代丁二酰亚胺(NBS) 、 三(1-萘基)膦 、 sodium carbonate 、 potassium carbonate 、 三苯基膦 、 palladium dichloride 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 39.5h， 生成 methyl 6-((4-(tert-butoxycarbonyl)phenyl)(16-((6-(methoxycarbonyl)pyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)picolinate
  参考文献：
  名称：

  [EN] MACROCYCLIC CHELATORS AND METHODS OF USE THEREOF
  [FR] CHÉLATEURS MACROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  提供了用于螯合α放射性金属离子（如锕-225）的大环螯合剂（I）。还提供了包含α放射性金属离子与大环螯合剂通过配位键结合的放射金属配合物，以及包含放射金属配合物共价连接到靶向配体（如抗体或其抗原结合片段）的放射免疫结合物。这些放射免疫结合物可以通过点击化学反应制备。还描述了利用这些放射金属配合物和放射免疫结合物用于选择性靶向肿瘤细胞进行放射治疗以及治疗肿瘤疾病和疾病的方法。

  公开号：

  WO2020229974A1
• 作为产物：
  描述：

  4-溴苯甲酸叔丁酯 在 sodium periodate 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 ammonium acetate 、 potassium acetate 作用下， 以 1,4-二氧六环 、 水 、 丙酮 为溶剂， 反应 48.0h， 生成 4-(叔丁氧基羰基)苯硼酸
  参考文献：
  名称：

  非配位阴离子的新方法：两性离子金属-有机骨架中卟啉金属中心的路易斯酸增强

  摘要：

  我们描述了一种使用两性离子金属有机框架 (MOF) 生成非配位阴离子的新策略。通过将阴离子无机二级结构单元 (SBU) ([In(CO2)4](-)) 与基于阳离子金属卟啉的有机连接体组装在一起，我们制备了两性离子 MOF，其中完全的内部电荷分离有效地防止了抗衡阴离子的潜在结合到阳离子金属中心。我们在三个代表性的电环化反应中证明了两性离子 MOF 中 Mn(III)-和 Fe(III)-卟啉的路易斯酸度增强：烯炔的 [2 + 1] 环化异构化，氮丙啶和烯烃的 [3 + 2] 环加成，以及[4 + 2] 醛与二烯的杂-Diels-Alder 环加成反应。这项工作为设计用于可调化学催化的功能性 MOF 铺平了道路。

  DOI：

  10.1021/jacs.6b05626
• 作为试剂：
  描述：

  4-(叔丁氧基羰基)苯基硼酸频哪醇酯 、 methyl 2-((6S,Z)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate 在 2-双环己基膦-2',6'-二甲氧基联苯 、 potassium fluoride 、 palladium diacetate 、 4-(叔丁氧基羰基)苯硼酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 t-butyl 4'-[(6S)-6-(2-methoxy-2-oxoethyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl][1,1'-biphenyl]-4-carboxylate
  参考文献：
  名称：

  SULFONAMIDE OR SULFINAMIDE COMPOUND HAVING EFFECT OF INDUCING BRD4 PROTEIN DEGRADATION AND PHARMACEUTICAL USE THEREOF

  摘要：

  所提供的是一个化合物或其药学上可接受的盐，该化合物在诱导BRD4蛋白降解方面表现出色，并且可用作癌症治疗药物。由下式(I) 表示的化合物或其药学上可接受的盐： 其中每个符号的含义如说明书中所述。

  公开号：

  EP4105220A1

文献信息

• [EN] AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'AZADÉCALINE EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：VIIV HEALTHCARE UK (NO 5) LTD

  公开号：WO2018002848A1

  公开（公告）日：2018-01-04

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula (I). These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物影响特性的化合物，其药物组合物和使用方法已列出。具体来说，提供了具有独特抗病毒活性的阿扎德卡林衍生物，作为HIV成熟抑制剂，如化合物(I)的公式所代表的那样。这些化合物对于治疗HIV和艾滋病是有用的。
• Pd-Catalyzed Cross-Coupling of Organostibines with Styrenes to Give Unsymmetric (<i>E</i>)-Stilbenes and (1<i>E</i>,3<i>E</i>)-1,4-Diarylbuta-1,3-dienes and Fluorescence Properties of the Products
  作者：Zhao Zhang、Dejiang Zhang、Longzhi Zhu、Dishu Zeng、Nobuaki Kambe、Renhua Qiu

  DOI：10.1021/acs.orglett.1c01532

  日期：2021.7.16

  A general and effective palladium-catalyzed cross-coupling of organostibines with styrenes to give (E)-olefins was disclosed. By the use of an organostibine reagent, this method can produce unsymmetric (E)-1,2-diarylethylenes and (1E,3E)-1,4-diarylbuta-1,3-dienes in good yields with high E/Z selectivity and good functional group tolerance. Resveratrol and DMU-212 were synthesized in high yield. The

  公开了一种通用且有效的钯催化的有机锑与苯乙烯的交叉偶联，以得到 ( E )-烯烃。通过使用有机锑试剂，该方法可以以良好的收率和高E / Z制备不对称的 ( E )-1,2-二芳基乙烯和 (1 E ,3 E )-1,4-二芳基丁二烯-1,3-二烯选择性和良好的官能团耐受性。白藜芦醇和 DMU-212 以高产率合成。该协议可以扩展到 (1 E ,3 E ,5 E )-1,6-diphenylhexa-1,3,5-triene的合成,产率为 40%。产品5e、5f和7a 显示出良好的光致发光量子产率，范围为 72% 至 99%。
• [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION<br/>[FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DU RÉCEPTEUR 4 ACTIVÉ PAR UNE PROTÉASE (PAR4) POUR LE TRAITEMENT DE L'AGRÉGATION PLAQUETTAIRE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013163279A1

  公开（公告）日：2013-10-31

  The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• [EN] 5- OR 7-AZAINDAZOLES AS BETA-LACTAMASE INHIBITORS<br/>[FR] AZAINDAZOLES EN 5 OU 7 UTILISÉS COMME INHIBITEURS DE BÊTA-LACTAMASE
  申请人：ACRAF

  公开号：WO2020178316A1

  公开（公告）日：2020-09-10

  The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacterial infection, alone or in combination with β-lactam antibiotics and/or other antibiotics and/or other β-lactamase inhibitors.

  本发明涉及具有以下一般式（I）的β-内酰胺酶抑制剂：其中R1-R4和X1-X2在规范中定义，其药物组成物，以及其用于治疗细菌感染的用途，单独或与β-内酰胺类抗生素和/或其他抗生素和/或其他β-内酰胺酶抑制剂结合使用。
• RorgammaT inhibitors
  申请人：MSD Oss B.V.

  公开号：EP2487159A1

  公开（公告）日：2012-08-15

  The present invention relates to compounds according to general Formula I or a pharmaceutically acceptable salt thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

  本发明涉及符合一般式I的化合物 或其药用可接受的盐。这些化合物可用于治疗RORgammaT介导的疾病或症状。